Table 1.
Effects of piroxicam and deracoxib on cell cycle phase distribution of CMT-U27 cells. Data are expressed as mean values ± standard error of means shown with *P < 0.05 versus control group.
| Drug concentrations | % G0/G1 | % S | % G2/M |
|---|---|---|---|
| Control | 45.23 ± 1.17 | 35.62 ± 2.57 | 19.16 ± 1.81 |
| Piroxicam (50 μM) | 55.93 ± 2.79 | 35.49 ± 1.92 | 8.58 ± 0.83 |
| Piroxicam (100 μM) | 58.44 ± 2.48 | 34.63 ± 2.25 | 6.93 ± 1.03 |
| Piroxicam (250 μM) | 70.31 ± 1.32 | 24.13 ± 2.06 | 5.56 ± 0.39 |
| Piroxicam (500 μM) | 80.22 ± 1.67* | 8.46 ± 0.77* | 11.32 ± 1.78 |
| Piroxicam (1000 μM) | 79.05 ± 2.19* | 11.93 ± 0.84* | 9.02 ± 0.51 |
| Deracoxib (50 μM) | 50.21 ± 2.55 | 41.35 ± 1.92 | 8.44 ± 1.10 |
| Deracoxib (100 μM) | 53.74 ± 2.12 | 42.51 ± 1.77 | 3.75 ± 0.29 |
| Deracoxib (250 μM) | 65.57 ± 1.45 | 15.04 ± 1.55 | 19.39 ± 1.29 |
| Deracoxib (500 μM) | 79.94 ± 2.14* | 14.03 ± 2.37 | 6.03 ± 0.53 |
| Deracoxib (1000 μM) | 71.34 ± 2.36* | 4.72 ± 0.85* | 23.94 ± 2.26 |